Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma
NCT ID: NCT05681234
Last Updated: 2023-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2022-08-24
2022-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tracer Targeting FAP PET Imaging in Patients
NCT05691894
68Ga-labeled NY105 PET Imaging in Patients
NCT05691881
Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy
NCT05828238
18F-FAPI PET/CT in Patients With Various Types of Cancer
NCT05810324
89Zr-labeled NY009 PET Imaging in Patients
NCT05691855
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
18F-RD2
18F-RD2
Patients will receive 5-10 mCi 18F-RD2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18F-RD2
Patients will receive 5-10 mCi 18F-RD2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients underwent PET/CT examination within 1 week;
3. Patients voluntarily signed informed consent;
4. Over 18 years old, male or female.
Exclusion Criteria
2. Lactating women;
3. Patients with impaired renal function.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Affiliated Hospital of Jiangnan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chunjing Yu
Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LS2021058
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.